An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.0 sites24 target enrollmentMarch 28, 2017

Overview

No summary available.

Registry

who.int

Start Date

March 28, 2017

End Date

TBD

Last Updated

9 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

Male

Sponsor

•1\. Male 7 \- 21 years of age
•2\. Diagnosis of DMD with a mutation that is amenable to exon 51
•skipping, confirmed by a genetic report
•3\. Stable dose of oral corticosteroids for at least 24 weeks or has not received corticosteroids for at least 24 weeks
•4\. Non\-ambulatory, or incapable of walking \=300 meters on the 6\-Minute Walk Test (6MWT)
•5\. Score of \=4 on the Brooke Score for Arms and Shoulders
•6\. Stable cardiac and pulmonary function
•7\. Use of contraceptives for sexually active males throughout the study
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 24

•1\. Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids)
•2\. Previous treatment with SMT C1100/BMN 195 at any time
•3\. Previous treatment with drisapersen (PRO051\) within the last 6 months
•4\. Participation in any other DMD interventional clinical study within 12 weeks
•5\. Major change in physiotherapy regimen within the past 3 months
•6\. Major surgery within 3 months
•7\. Presence of other clinically significant illness
•8\. Use of an aminoglycoside antibiotic within 12 weeks or the need for this antibiotic or statin during study
•9\. Forced vital capacity % predicted \[FVC % predicted] \<40%, or requiring daytime ventilation
•10\. Require antiarrhythmic and/or antidiuretic therapy for heart failure